Skip to main content
NCBI home page
Cancer Biomarkers: Section A of Disease Markers logoLink to Cancer Biomarkers: Section A of Disease Markers
. 2016 Mar 30;16(3):367–376. doi: 10.3233/CBM-160575

MicroRNAs contribution in tumor microenvironment of esophageal cancer

Nazila Nouraee a, Samaneh Khazaei a,b, Mohammad Vasei c, Seyedeh Fatemeh Razavipour a,b, Majid Sadeghizadeh a, Seyed Javad Mowla a,*
PMCID: PMC13016487  PMID: 26889983

Abstract

BACKGROUND:

miRNAs have recently been implicated in tumor's microenvironment remodeling and tumor-stromal cells interactions. We have previously reported a signaling role for miR-21, as a secretory molecule released by cancer associated fibroblasts (CAF) adjacent to esophagus tumor cells.

OBJECTIVE:

To discover other potential signaling miRNAs, we employed a co-culture system of esophageal cancer cell line and normal fibroblasts to mimic the tumor microenvironment.

METHODS:

We measured the expression profile of secretory miRNAs in the conditioned media (CM) of our co-culture system using a panel PCR array. We used pathway enrichment analysis to define potential pathways regulated by these miRNAs. Then using ultracentrifugation, we purified exosomes secreted to the CM of co-cultured cell lines and evaluated exosomal secretion of these miRNAs.

RESULTS:

We found 18 miRNAs which were significantly up/down-regulated in the CM of co-culture system. Pathways related to cell adhesion, endocytosis and cell junctions were among the enriched pathways that might be related to CAF phenotype and tumor progression. Moreover, we detected higher exosomal levels of miR-33a and miR-326 in the purified exosomes both in co-cultured and untreated CM. So, these miRNAs are mainly secreted into the CM by means of exosomes.

CONCLUSIONS:

Briefly, our data shed more light on the role of CAFs through secretion of miRNAs within tumor microenvironment and propose novel therapeutic targets for esophageal and probably other cancer types.

Keywords: Esophageal cancer, secretory microRNA, profiling, tumor microenvironment, stroma, exosome, cancer associated fibroblasts

Full Text

The Full Text of this article is available as a PDF (1.2 MB).

References

  • [1]. Nouraee N., Mowla S. and Calin G., Tracking miRNAs' footprints in tumor-microenvironment interactions: insights and implications for targeted cancer therapy. Genes Chromosomes Cancer 54 (2015), p. 335-352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [2]. Grivennikov S. and Karin M., Inflammatory cytokines in cancer: Tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis 70 (2011), p. i104-i108. [DOI] [PubMed] [Google Scholar]
  • [3]. Balkwill F., Tumour necrosis factor and cancer. Nat Rev Cancer 9 (2009), p. 361-371. [DOI] [PubMed] [Google Scholar]
  • [4]. Tian T., Zhu Y., Zhou Y., et al., Exosome Uptake through Clathrin-mediated Endocytosis and Macropinocytosis and Mediating miR-21 Delivery. J Biol Chem 289 (2014), p. 22258-22267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [5]. Castellana D., Zobairi F., Martinez M., et al., Membrane Microvesicles as Actors in the Establishment of a Favorable Prostatic Tumoral Niche: A Role for Activated Fibroblasts and CX3CL1-CX3CR1 Axis. Cancer Res 69 (2009), p. 785-793. [DOI] [PubMed] [Google Scholar]
  • [6]. Atay S. and Godwin A., Tumor-derived exosomes: A message delivery system for tumor progression. Commun Integr Biol 7 (2014), p. e28231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [7]. Nouraee N., Van Roosbroeck K., Vasei M., et al., Expression, tissue distribution and function of miR-21 in esophageal squamous cell carcinoma. PLoS One 8 (2013), p. e73009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [8]. Thery C., Amigorena S., Raposo G., et al., Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol 30 (2006), p. 3.22. [DOI] [PubMed] [Google Scholar]
  • [9]. Nouraee N. and Calin G., MicroRNAs as Cancer Biomarkers. MicroRNA 2 (2013), p. 102-117. [DOI] [PubMed] [Google Scholar]
  • [10]. Mitra A., Zillhardt M., Hua Y., et al., MicroRNAs Reprogram Normal Fibroblasts into Cancer-Associated Fibroblasts in Ovarian Cancer. Cancer Discov 2 (2012), p. 1100-1108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [11]. Suetsugu A., Hiroshima Y., Matsumoto T., et al., Recruitment of Cancer-Associated Fibroblasts and Blood Vessels by Orthotopic Liver Tumors Imaged in Red Fluorescent Protein (RFP) Transgenic Nude Mice. Anticancer Res 35 (2015), p. 5821-5. [PubMed] [Google Scholar]
  • [12]. Suetsugu A., Osawa Y., Nagaki M., et al., Imaging the recruitment of cancer-associated fibroblasts by liver-metastatic colon cancer. J Cell Biochem 112 (2011), p. 949-53. [DOI] [PubMed] [Google Scholar]
  • [13]. Suetsugu A., Katz M., Fleming J., et al., Multi-color palette of fluorescent proteins for imaging the tumor microenvironment of orthotopic tumorgraft mouse models of clinical pancreatic cancer specimens. J Cell Biochem 113 (2012), p. 2290-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [14]. Peinado H., Aleckovic M., Lavotshkin S., et al., Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 18 (2012), p. 883-891. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [15]. Suetsugu A., Honma K., Saji S., et al., Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models. Adv Drug Deliv Rev 65 (2013), p. 383-90. [DOI] [PubMed] [Google Scholar]
  • [16]. Fabbri M., Paone A., Calore F., et al., MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. PNAS 109 (2012), p. E2110-E2116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [17]. Soon P. and Kiaris H., MicroRNAs in the tumour microenvironment: Big role for small players. Endocr Relat Cancer 20 (2013), p. R257-R267. [DOI] [PubMed] [Google Scholar]
  • [18]. Hannafon B. and Ding W., Intercellular communication by exosome-derived microRNAs in cancer. Int. J. Mol. Sci. 14 (2013), p. 14240-14269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [19]. Kao S., Wang W., Chen C., et al., GSK3β controls epithelial-mesenchymal transition and tumor metastasis by CHIP-mediated degradation of Slug. Oncogene 33 (2014), p. 3172-3182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [20]. Yi Y., Nagyova E., Manandhar G., et al., Proteolytic activity of the 26S proteasome is required for the meiotic resumption, germinal vesicle breakdown, and cumulus expansion of porcine cumulus-oocyte complexes matured in vitro. Biol Reprod 78 (2008), p. 115-126. [DOI] [PubMed] [Google Scholar]
  • [21]. Grivennikov S., Greten F. and Karin M., Immunity, inflammation, and cancer. Cell 140 (2010), p. 883-899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [22]. Klampfer L., Cytokines, inflammation and colon cancer. Curr Cancer Drug Targets 11 (2011), p. 451-464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [23]. Lane R., Korbie D., Anderson W., et al., Analysis of exosome purification methods using a model liposome system and tunable-resistive pulse sensing. Sci Rep 5 (2015), p. 7639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [24]. Wang H., Sun T., Hu J., et al., miR-33a promotes glioma-initiating cell self-renewal via PKA and NOTCH pathways. J Clin Invest 124 (2014), p. 4489-4502. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [25]. Zhou Y., Huang Z., Wu S., et al., miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST. J Exp Clin Cancer Res 33 (2014), p. 12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [26]. Takeshita H., Shiozaki A., Bai X., et al., XB130, a new adaptor protein, regulates expression of tumor suppressive microRNAs in cancer cells. PLoS One 8 (2013), p. e59057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [27]. Thomas M., Lange-Grunweller K., Weirauch U., et al., The proto-oncogene Pim-1 is a target of miR-33a. Oncogene 31 (2012), p. 918-928. [DOI] [PubMed] [Google Scholar]
  • [28]. Ibrahim A., Weirauch U., Thomas M., et al., MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res 71 (2011), p. 5214-5224. [DOI] [PubMed] [Google Scholar]
  • [29]. Fang Y., Feng Y., Wu T., et al., Aflatoxin B1 negatively regulates Wnt/β -catenin signaling pathway through activating miR-33a. PLoS One 8 (2013), p. e73004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [30]. Kano M., Seki N., Kikkawa N., et al., miR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 127 (2010), p. 2804-2814. [DOI] [PubMed] [Google Scholar]
  • [31]. Qiu T., Zhou X., Wang J., et al., MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer. FEBS Lett 588 (2014), p. 1168-1177. [DOI] [PubMed] [Google Scholar]
  • [32]. Townley-Tilson W., Callis T. and Wang D., MicroRNAs 1, 133, and 206: critical factors of skeletal and cardiac muscle development, function, and disease. Int J Biochem Cell Biol 42 (2010), p. 1252-1255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [33]. Kawakami K., Enokida H., Chiyomaru T., et al., The functional significance of miR-1 and miR-133a in renal cell carcinoma. Eur J Cancer 48 (2012), p. 827-836. [DOI] [PubMed] [Google Scholar]
  • [34]. Rao P., Missiaglia E., Shields L., et al., Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells. FASEB J 24 (2010), p. 3427-3437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [35]. Li T., Xie J., Shen C., et al., miR-150-5p inhibits hepatoma cell migration and invasion by targeting MMP14. PLoS One 9 (2014), p. e115577. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]

Articles from Cancer Biomarkers: Section A of Disease Markers are provided here courtesy of SAGE Publications

RESOURCES